NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer ...

EIK1003-001 (Abstract # CT197): A first-in-human, Phase 1/2 dose escalation, dose-optimization, and dose-expansion trial of PARP1-selective inhibitor EIK1003 in patients with advanced solid tumors.

RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical ...

Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients ...

Century Therapeutics, Inc. (NASDAQ: IPSC) has announced its participation in the upcoming European Alliance of Associations ...

Onsite Parexel experts include recently appointed Chief Medical Officer and veteran oncologist Dr. Charlotte Moser, licensed medical oncologist and Global Therapeutic Area Head, Oncology, Dr. Gwyn ...

Cerus Corporation today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to ...

Insulin efsitora alfa (investigational once-weekly basal insulin): In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated ...

With the advancement of medical imaging, the diagnosis and treatment of various conditions have undergone a revolution. Recently, artificial intelligence, ...

Favorable safety and tolerability, with promising early activity of novel mRNA-based therapy observed from interim data– ...